TY - JOUR T1 - Home-based pulmonary rehabilitation early after hospitalisation in COPD (early HomeBase): protocol for a randomised controlled trial JF - BMJ Open Respiratory Research JO - BMJ Open Resp Res DO - 10.1136/bmjresp-2021-001107 VL - 8 IS - 1 SP - e001107 AU - Narelle S Cox AU - Aroub Lahham AU - Christine F McDonald AU - Ajay Mahal AU - Paul O'Halloran AU - Graham Hepworth AU - Lissa Spencer AU - Renae J McNamara AU - Janet Bondarenko AU - Heather Macdonald AU - Samantha Gavin AU - Angela T Burge AU - Caitlin Le Maitre AU - Cade Ringin AU - Elizabeth Webb AU - Amanda Nichols AU - Ling-Ling Tsai AU - Nia Luxton AU - Stephanie van Hilten AU - Mary Santos AU - Hayley Crute AU - Megan Byrne AU - Helen Boursinos AU - Jennifer Broe AU - Monique Corbett AU - Tunya Marceau AU - Brooke Warrick AU - Claire Boote AU - Joanna Melinz AU - Anne E Holland Y1 - 2021/11/01 UR - http://bmjopenrespres.bmj.com/content/8/1/e001107.abstract N2 - Introduction Chronic obstructive pulmonary disease (COPD) is characterised by exacerbations of respiratory disease, frequently requiring hospital admission. Pulmonary rehabilitation can reduce the likelihood of future hospitalisation, but programme uptake is poor. This study aims to compare hospital readmission rates, clinical outcomes and costs between people with COPD who undertake a home-based programme of pulmonary rehabilitation commenced early (within 2 weeks) of hospital discharge with usual care.Methods A multisite randomised controlled trial, powered for superiority, will be conducted in Australia. Eligible patients admitted to one of the participating sites for an exacerbation of COPD will be invited to participate. Participants will be randomised 1:1. Intervention group participants will undertake an 8-week programme of home-based pulmonary rehabilitation commencing within 2 weeks of hospital discharge. Control group participants will receive usual care and a weekly phone call for attention control. Outcomes will be measured by a blinded assessor at baseline, after the intervention (week 9–10 posthospital discharge), and at 12 months follow-up. The primary outcome is hospital readmission at 12 months follow-up.Ethics and dissemination Human Research Ethics approval for all sites provided by Alfred Health (Project 51216). Findings will be published in peer-reviewed journals, conferences and lay publications.Trial registration number ACTRN12619001122145. ER -